Thrombocytopenic Disorder — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for thrombocytopenic disorder. 3 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
3
Active US patents
25/100
Avg vulnerability
—
Annual revenue covered

Originators in Thrombocytopenic Disorder

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Vancocin Italia 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating thrombocytopenic disorder. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
28
1
30
1
31

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Mulpleta
LUSUTROMBOPAG
 Vancocin Italia 3 25 — 2028-07-29

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9427402 Mulpleta formulation 48 2031-09-29
8889722 Mulpleta composition of matter 17 2028-07-29
8530668 Mulpleta composition of matter 10 2030-01-21

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8530668 Mulpleta composition of matter 10 2030-01-21
8889722 Mulpleta composition of matter 17 2028-07-29
9427402 Mulpleta formulation 48 2031-09-29

Related